You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

DUBLIN, March 19, 2020 /PRNewswire/ -- The "Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering. This report on the multiple sclerosis drugs market studies the past as well as the current growth trends and opportunities, to gain valuable insights of the same indicators for the market over the forecast period from 2019 to 2027. The report provides the overall market revenue of the multiple sclerosis drugs market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the multiple sclerosis drugs market for the forecast period 2019-2027.The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the multiple sclerosis drugs market.Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approach to study various phenomena in the multiple sclerosis drugs market.The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the multiple sclerosis drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the multiple sclerosis drugs market.The report also delves into the competitive landscape of the multiple sclerosis drugs market. Key players operating in the multiple sclerosis drugs market have been identified and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the multiple sclerosis drugs market that have been profiled in this report.Key Questions Answered How does the development of multiple sclerosis drugs provide the scope of growth in the multiple sclerosis drugs market? How alliances and partnerships between players are widening the scope of new line of treatment for multiple sclerosis? What are the revenue share projections of key segments under various criteria in the multiple sclerosis drugs market during the forecast period? Which segment is likely to register leading revenue until the end of the forecast period in 2027? How is the evolving healthcare system in developing countries of Asia Pacific making an impact on the overall multiple sclerosis drugs market? Key Topics Covered: 1. Preface2. Assumptions and Research Methodology3. Executive Summary: Global Multiple Sclerosis Drugs Market4. Market Overview4.1. Introduction4.1.1. Multiple Sclerosis Drugs Market Introduction4.1.2. Industry Evolution / Developments4.2. Overview4.3. Market Dynamics4.3.1. Drivers4.3.2. Restraints4.3.3. Opportunities4.4. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2017-20274.4.1. Market Revenue Projections (US$ Mn)5. Key Insights5.1. Pipeline Analysis5.2. Regulatory Scenario5.3. Disease Epidemiology5.4. Market Access Overview5.5. Key Mergers & Acquisitions 6. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Drug Class 6.1. Introduction & Definition6.2. Key Findings / Developments6.3. Market Value Forecast, by Drug Class, 2017-20276.3.1. Interferon Beta6.3.2. Sphingosine 1 Phosphate Receptor Modulators6.3.3. Mixed Polymers6.3.4. NF-B Inhibitor6.3.5. Pyrimidine Synthesis Inhibitor6.3.6. Monoclonal Antibodies6.3.7. Corticosteroids6.3.8. Adrenocorticotropic Hormone6.3.9. Others6.4. Market Attractiveness, by Drug Class 7. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Disease Type 7.1. Introduction & Definition7.2. Key Findings / Developments7.3. Market Value Forecast, by Disease Type, 2017-20277.3.1. Relapsing-remitting MS (RRMS)7.3.2. Primary-progressive MS (PPMS)7.3.3. Secondary-progressive MS (SPMS)7.3.4. Progressive-relapsing MS (PRMS)7.4. Market Attractiveness, by Disease Type 8. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Route of Administration 8.1. Introduction & Definition8.2. Key Findings / Developments8.3. Market Value Forecast, by Route of Administration, 2017-20278.3.1. Parenteral8.3.2. Oral8.4. Market Attractiveness by Route of Administration 9. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Distribution Channel 9.1. Introduction & Definition9.2. Key Findings / Developments9.3. Market Value Forecast, by Distribution Channel, 2017-20279.3.1. Hospital Pharmacies9.3.2. Retail Pharmacies & Drug Stores9.3.3. Online Pharmacies9.4. Market Attractiveness, by Distribution Channel 10. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Region10.1. Key Findings10.2. Market Value Forecast, by Region10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness, by Country/Region11. North America Multiple Sclerosis Drugs Market Analysis and Forecast11.1. Introduction11.1.1. Key Findings11.2. Market Value Forecast, by Drug Class, 2017-202711.2.1. Interferon Beta11.2.2. Sphingosine 1 Phosphate Receptor Modulators11.2.3. Mixed Polymers11.2.4. NF-B Inhibitor11.2.5. Pyrimidine Synthesis Inhibitor11.2.6. Monoclonal Antibodies11.2.7. Corticosteroids11.2.8. Adrenocorticotropic Hormone11.2.9. Others11.3. Market Value Forecast, by Disease Type, 2017-202711.3.1. Relapsing-remitting MS (RRMS)11.3.2. Primary-progressive MS (PPMS)11.3.3. Secondary-progressive MS (SPMS)11.3.4. Progressive-relapsing MS (PRMS)11.4. Market Value Forecast, by Route of Administration, 2017-202711.4.1. Parenteral11.4.2. Oral11.5. Market Value Forecast, by Distribution Channel, 2017-202711.5.1. Hospital Pharmacies11.5.2. Retail Pharmacies & Drug Stores11.5.3. Online Pharmacies11.6. Market Value Forecast, by Country, 2017-202711.6.1. U.S.11.6.2. Canada11.7. Market Attractiveness Analysis 11.7.1. By Drug Class 11.7.2. By Disease Type 11.7.3. By Route of Administration 11.7.4. By Distribution Channel 11.7.5. By Country12. Europe Multiple Sclerosis Drugs Market Analysis and Forecast13. Asia Pacific Multiple Sclerosis Drugs Market Analysis and Forecast14. Latin America Multiple Sclerosis Drugs Market Analysis and Forecast15. Middle East & Africa Multiple Sclerosis Drugs Market Analysis and Forecast16. Competition Landscape16.1. Market Share Analysis, by Company, 201816.2. Company Profiles Companies Mentioned Bayer AG Teva Pharmaceutical Industries Ltd. Novartis AG Sanofi F. Hoffmann-La Roche Ltd. Celgene Corporation Acorda Therapeutics, Inc. Biogen, Inc. Actelion Pharmaceuticals (Johnson & Johnson) EMD Serono (Merck KGaA) AbbVie, Inc. For more information about this report visit https://www.researchandmarkets.com/r/w3vqa4 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Research and Markets Laura Wood, Senior Manager [emailprotected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com

Answer: Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast (2019 to 2027)